CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 599 enrolled
Drug / intervention
alitretinoin +1 moredrug
Likely dose
alitretinoin 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00817063
NCT00817063Phase 3Completed
CompareCT.gov

Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy

Stiefel, a GSK Company·interventional·Posted Jan 6, 2009·Updated Apr 27, 2020

In Brief

A Phase 3 clinical trial evaluating alitretinoin and Placebo for Eczema. Completed, enrolled 599 participants across 70 sites.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEczema
CountriesUnited States
CollaboratorsBasilea Pharmaceutica

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 6, 2009
Enrollment StartJan 8, 2009
Primary CompletionApr 26, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.5 years ago

Interventions

alitretinoindrug

Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks

Placebodrug

Patients receive matching placebo for up to 24 weeks